TABLE 5.

Mortality rates (21 day) in 97 ESBL-BSI patients initially treated with antimicrobial agents to which the infecting organism displayed in vitro susceptibility

Antimicrobial agents administered (n)	No. (%) of patients		OR (95% CI)	P
	Nonsurvivors (n = 18)	Survivors (n = 79)
Aminoglycosides (20)	5 (27.8)	15 (19)	1.48 (0.59-3.66)	0.40
β-Lactam-β-lactamase inhibitors (33)	4 (22.2)	29 (36.7)	0.55 (0.19-1.55)	0.24
Carbapenems (28)	1 (5.5)	27 (34.2)	0.14 (0.02-1.03)	0.01
Ciprofloxacin (16)	8 (44.4)	8 (10.1)	4.05 (1.89-8.65)	<0.001